LumiThera Acquires MacuLogix Assets (AdaptDx Pro)
July 26, 2022
LumiThera, through a wholly owned subsidiary, purchased the assets of MacuLogix, including the AdaptDx Pro dark adaptometer used for early diagnosis of dry age-related macular degeneration (AMD). The acquisition expands LumiThera's diagnostic and monitoring capabilities and complements its Valeda photobiomodulation treatment platform for dry AMD patients.
- Buyers
- LumiThera, Inc.
- Targets
- MacuLogix, Inc.
- Sellers
- MacuLogix, Inc.
- Industry
- Medical Devices
- Location
- Pennsylvania, United States
- Transaction Type
- Buyout
Explore More
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.